Business Context and Reporting Period
Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 28, 2001
Business Overview: The Company is a leading developer and manufacturer of power sources, feedthroughs, and wet tantalum capacitors for implantable medical devices (pacemakers, ICDs). It also manufactures commercial power sources for aerospace, oil and gas exploration, and oceanographic equipment. The Company operates two reportable segments: Medical and Commercial Power Sources.
Key Financial Metrics
| Metric | 2001 | 2000 |
|---|---|---|
| Total Revenues | $135.6 million | $97.8 million |
| Gross Profit | $60.9 million | $42.3 million |
| Gross Margin | 45% | 43% |
| Net Income | $8.6 million | $(0.5) million |
| Diluted EPS | $0.43 | $(0.04) |
| Cash and Cash Equivalents | $43.3 million | $0.016 million |
| Operating Cash Flow | $21.5 million | $18.2 million |
| Long-Term Obligations | $61.4 million | $31.0 million |
| Total Assets | $283.5 million | $181.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 39% to $135.6 million, driven by a 28% increase in medical revenues and a 99% increase in commercial revenues.
- Acquisitions: The acquisition of Greatbatch-Sierra (June 2001) contributed significantly to medical component revenues and backlog. The inclusion of a full year of Battery Engineering, Inc. (BEI) results boosted commercial revenues.
- Profitability: The Company returned to profitability with $8.6 million in net income, compared to a net loss of $0.5 million in 2000. This was primarily due to a 72% reduction in net interest expense and improved gross margins.
- Debt Restructuring: The Company refinanced its debt in 2001, reducing interest rates and extending maturities. However, total debt increased due to borrowing $47.0 million to finance the Sierra acquisition.
- Intangible Assets: Net intangible assets rose to $137.1 million (48% of total assets) due to goodwill and technology acquired in recent purchases.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures to increase in 2002 for production capacity and R&D expansion. The Company anticipates continued growth in the implantable medical device industry, particularly in ICDs.
- Customer Concentration: Two customers (Guidant and St. Jude Medical) accounted for approximately 66% of 2001 revenues. The loss of either would materially harm the business.
- Raw Materials: The Company relies on third-party suppliers for critical materials like lithium, tantalum, and platinum. Recent global demand has caused significant price increases for some of these materials.
- Accounting Changes: The Company adopted SFAS No. 142 effective December 29, 2001. Goodwill and indefinite-life intangibles will no longer be amortized but will be tested for impairment annually.
- Patent Expirations: Several key patents are set to expire between 2006 and 2019. The expiration of three pacemaker battery patents in 2001 resulted in the termination of royalty payments from Medtronic.
Investor Verification Checklist
- Customer Dependency: Verify the status of supply agreements with Guidant (expires 2004) and St. Jude Medical (expires 2003), which represent the majority of revenue.
- Intangible Asset Valuation: Assess the risk of impairment charges on the $137.1 million in intangible assets, particularly given the new SFAS No. 142 impairment testing requirements.
- Raw Material Costs: Monitor price volatility for lithium, tantalum, and platinum, which could compress gross margins if not passed through to customers.
- Debt Covenants: Review compliance with the $100 million credit facility covenants related to EBITDA and leverage ratios.
- Patent Portfolio: Confirm the timeline for patent expirations and the status of new product development (e.g., rechargeable lithium-ion batteries) to maintain competitive advantage.